Skip to main content

Table 11 Framingham risk score according clinical lipodystrophy and metabolic syndrome

From: Impact of Lipodystrophy on the prevalence and components of metabolic syndrome in HIV-infected patients

  Without clinical lipodystrophy With clinical lipodystrophy
Framingham risk score Without MS With MS Total Without MS With MS Total
Low risk (< 5%) [n (%)] 27 (45.8) 20 (29.4) 47 (37.0) 36 (41.9) 23 (21.5) 59 (30.6)
Average (5%-9%) [n (%)] 21 (35.6) 22 (32.4) 43 (33.9) 31 (36.0) 31 (29.0) 62 (32.1)
Moderate risk (10-19%) [n (%)] 7 (11.9) 13 (19.1) 20 (15.7) 15 (17.4) 31 (29.0) 46 (23.8)
High risk (20-39%) [n (%)] 3 (5.1) 12 (17.6) 15 (11.8) 2 (2.3) 20 (18.7) 22 (11.4)
Very high risk (> 40%) [n (%)] 1 (1.7) 1 (1.5) 2 (1.6) 2 (2.3) 2 (1.9) 4 (2.1)
p 0.078 < 0.001